Patents Assigned to Phoenix Pharmacologics, Inc.
  • Methods for inhibiting viral replication in vivo
    Patent number: 7204980
    Abstract: The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: April 17, 2007
    Assignee: Phoenix Pharmacologics, Inc.
    Inventor: Mike Clark
  • Modified tumor necrosis factor
    Publication number: 20060222626
    Abstract: Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.
    Type: Application
    Filed: February 27, 2006
    Publication date: October 5, 2006
    Applicant: Phoenix Pharmacologics, Inc.
    Inventor: Mike Clark
  • Peg-Modified Uricase
    Publication number: 20050226859
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Application
    Filed: May 27, 2005
    Publication date: October 13, 2005
    Applicant: Phoenix Pharmacologics, Inc.
    Inventors: Charles Ensor, Mike Clark, Frederick Holtsberg
  • PEG-modified uricase
    Patent number: 6913915
    Abstract: The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
    Type: Grant
    Filed: August 2, 2001
    Date of Patent: July 5, 2005
    Assignee: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Mike A. Clark, Frederick Wayne Holtsberg
  • Novel mutated form of arginine deiminase
    Publication number: 20040258675
    Abstract: The present invention discloses arginine deiminase that is genetically modified for more efficient manufacturing and processing. The present invention discloses recombinant DNA molecules and vectors and other therapeutic and pharmaceutical compositions. The present invention also discloses methods for preparing modified arginine deiminase as well as methods of treating cancer and other disease states using modified arginine deiminase.
    Type: Application
    Filed: August 21, 2003
    Publication date: December 23, 2004
    Applicant: Phoenix Pharmacologics, Inc.
    Inventors: Charles Mark Ensor, Frederick Wayne Holtsberg, Mike A. Clark
  • Modified arginine deiminase
    Patent number: 6737259
    Abstract: The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods of treating cancer, and to methods of treating and/or inhibiting metastasis.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: May 18, 2004
    Assignee: Phoenix Pharmacologics, Inc.
    Inventor: Mike A. Clark